logomg.png
Open Demat Account
Open Demat Account

  • SENSEX

    {{sensexData[0].price}} (+{{sensexData[0].change}}%)

  • SENSEX

    {{sensexData[0].price}} ({{sensexData[0].change}}%)

  • NIFTY 50

    {{niftyData[0].open_price}} (+{{niftyData[0].change}}%)

  • NIFTY 50

    {{niftyData[0].open_price}} ({{niftyData[0].change}}%)

  • {{mcxData[2].symbol}}

    {{mcxData[2].price}} (+{{mcxData[2].PerChange}}%)

  • {{mcxData[2].symbol}}

    {{mcxData[2].price}} ({{mcxData[2].PerChange}}%)

  • {{mcxData[0].symbol}}

    {{mcxData[0].price}} (+{{mcxData[0].PerChange}}%)

  • {{mcxData[0].symbol}}

    {{mcxData[0].price}} ({{mcxData[0].PerChange}}%)

  • {{mcxData[1].symbol}}

    {{mcxData[1].price}} (+{{mcxData[1].PerChange}}%)

  • {{mcxData[1].symbol}}

    {{mcxData[1].price}} ({{mcxData[1].PerChange}}%)

  • {{mcxData[3].symbol}}

    {{mcxData[3].price}} (+{{mcxData[3].PerChange}}%)

  • {{mcxData[3].symbol}}

    {{mcxData[3].price}} ({{mcxData[3].PerChange}}%)

Back
Laurus Labs slides after Q4 PAT tumbles 26% YoY to 76 cr 
(16:33, 25 Apr 2024)
Revenue from operations increased 4.26% to ₹ 1,439.67 crore in Q4 FY24 as compared with ₹ 1380.90 crore posted in corresponding quarter last year. The said growth was driven by continued strength in FDF and good sequential recovery across CDMO, API business.

Profit before tax fell 27.1% YoY to ₹ 107.27 crore in Q4 FY24.

EBITDA fell 10% to ₹ 259 crore in Q4 FY24 from ₹ 287 crore posted in Q4 FY23.EBITDA margin reduced by 280 bps to 18% in Q4 FY24 as against 20.8% in Q4 FY23.

Research and development (R&D) spends reported at ₹ 69 crore and around 4.8% of revenues; Higher spends over last year partly due to additional spend towards CGT space.

The pharma company?s formulation business grew 9% to ₹ 430 crore in the quarter ended 31 March 2024 as compared with ₹ 393 crore in the quarter ended 31 March 2023.

Income from API business jumped 4% YoY to ₹ 745 crore, supported from growth across franchise despite continuing pricing pressure in other APIs segment. As on 31 March 2024, the company has filed 342 patents out of that 228 patents granted. Cumulative DMFs filings stood at 83.

In Q4 FY24, CDMO-Synthesis business reported revenue of ₹ 236 crore, up 4% YoY. Bio-transformation & Continuous Flow platform witnessed strong customer interest driven by rising complexity, faster time to market further fueled by increasing sustainability pressure.

Revenue from Laurus Bio division tumbled 37% YoY to ₹ 29 crore, mainly transitionary in nature due to customer order cyclicality.

Meanwhile, the company?s board has declared a dividend of ₹ 0.40 per share of face value of ₹ 2 each for financial year 2023-2024. It has fixed 8 May 2024 as record date for determining the eligibility of the shareholders. The dividend amount will be paid on or after 17 May 2024.

Satyanarayana Chava , founder and chief executive officer, said, ?Laurus core results reflects continued resilience across our business divisions despite discontinuation of Covid related products purchase orders. We delivered underlying revenue growth of 9% driven by strong performance in FDF, CDMO, Onco API and Bio division.

In the CDMO space, we are delivering on multiple RFPs involving higher chemical complexity and scale with increased customer engagement focusing on several sustainable technology platforms. Our on-going innovative CGT investment continue to report significant updates for the period under review, especially successful NexCAR19 commercial launch in India to treat cancers

We are entering FY25 with solid foundation and remain committed to grow by focusing on R&D led commercial excellence. We are prioritizing efforts to improve margin, particularly increasing asset utilization across network and delivering late phase commercial opportunity.?

V.V. Ravi Kumar, executive director & chief financial officer, said, ?Overall FY24 reported operating result was challenging driven by selling price decline in ARV products, absence of large PO, and continued OPEX on growth projects/new initiatives. We achieved ₹ 5,041 crore in revenues, representing 17% decline. Excluding the large PO the underlying growth was 9% over last year.

Gross margin was 51.7% and EBITDA at ₹ 798 crore resulting in 15.8% margin. The EBIDTA margin for the Q4FY24 is at 18.0% and reflecting sequential improvement. Despite operational challenges, our committed capacity built-up is on track and continuing our focus on productivity improvement. Going ahead, we are fully focusing on gradually returning to growth, prioritising investments in high value segments, improving Net debt leverage while defining our strategic roadmap to ensure long-term profitable and sustainable growth.?

Laurus Labs is a fully integrated pharmaceutical and biotechnology company, with a leadership position in generic active pharmaceutical ingredients (APIs) and a major focus on anti-retroviral, oncology drugs, cardiovascular, gastro and hepatitis C therapeutics. The company also develops and manufactures oral solid formulations, provide contract research and manufacturing services (CRAMS) to global pharma companies.

Powered by Capital Market - Live News

No Details of this news available

Mandatory Dematerialization for Transfer of Securities, w.e.f 5th December 2018. Refer to SEBI notification number SEBI/LAD-NRO/GN/2018/24 dated June 08,2018.

Update/Link your Aadhaar Number with your Demat Account by Submitting a photocopy of Aadhaar card along with a request letter/Modification form.

Prevent Unauthorised transactions in your account. Update your mobile numbers/email IDs with your stock brokers.

KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorize your bank to make payment in case of allotment.

Prevent Unauthorized Transactions in your demat account. Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day....... Issued in the interest of investors.

Prevent unauthorized transactions in your trading account ->Update your mobile numbers/email IDs with your stock brokers. Receive information/alerts of your transactions directly from Exchange on your mobile/email at the end of the day.... Issued in the interest of investors.

Filing Complaints on SCORES - Easy & quick.
a. Register on SCORES portal,
b. Provide mandatory details for filing complaints on SCORES like name, PAN, address, mobile number, email ID.
c. Benefits:
   i. Effective communication
   ii. Speedy redressal of the grievances

Investor Awareness regarding the revised guidelines on margin collection

 

Dear Investor,

As you are aware, under the rapidly evolving dynamics of financial markets, it is crucial for investors to remain updated and well-informed about various aspects of investing in securities market. In this connection, please find a link to the BSE Investor Protection Fund website where you will find some useful educative material in the form of text and videos, so as to become an informed investor.

https://www.bseipf.com/investors_education.html

We believe that an educated investor is a protected investor !!!

 

Risk Disclosure on Derivatives

  • out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:
SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

MAGNUM EQUITY BROKING LTD.

SEBI Registration No.: INZ000172031 NSE Member ID: 06529 | BSE Clearing No.:126 | CDSL SEBI Registration No. IN-DP-CDSL-201-2003
DP ID: 12029700 | CIN: U67120MH1996PLC103441

Investor Grievances: grievances@magnum.co.in

Copyright © 2018-2019 Magnum Equity Broking Ltd. All rights reserved

Designed, Developed & Powered by CMOTS Infotech (ISO 9001:2015 Certified)